Protagonist Therapeutics to Present Rusfertide Phase 3 Data on Hematocrit Control at EHA 2026

Protagonist Therapeutics will present findings from its Phase 3 VERIFY trial and long-term data regarding rusfertide at the 2026 European Hematology Association (EHA) Congress. The presentations will cover the efficacy and safety of rusfertide in treating polycythemia vera.

The VERIFY trial data will detail how rusfertide maintained hematocrit control and reduced the need for phlebotomies in patients with polycythemia vera. The long-term data on rusfertide will provide additional insights into its sustained efficacy and safety profile over an extended period. These findings aim to offer a comprehensive understanding of rusfertide’s potential as a treatment option for individuals affected by polycythemia vera.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI